Foundational Technology for Biological Therapies
Humanity faces significant health challenges, with increasing rates of cancer, rare diseases, and aging-related conditions. Current treatments often have limitations, leading to low effectiveness and severe side effects. Thus, the urgent need for new, effective, and safer treatments is crucial.
GPIA was founded with the mission to pioneer the research and development of advanced and effective biological therapies, offering new hope for treating incurable diseases without the pain of conventional therapies like radiation. GPIA's core research technology includes three main platforms, accompanied by applied technology products and services:
Mitochondrial Platform:
Research Technology:
Mitochondrial Gene Editing: Use advanced gene editing tools like CRISPR/Cas9 to repair disease-causing mitochondrial gene mutations.
Mitochondrial Transplantation: Transplant healthy mitochondria from donors into patients' bodies to replace damaged mitochondria.
Mitochondrial Function Modulation: Develop small molecules or gene therapies to modulate mitochondrial function, improve energy production efficiency, and reduce oxidative stress.
Applied Technology:
Develop potential mitochondrial stem cell therapies for neurodegenerative diseases like Parkinson's and Alzheimer's, cardiovascular diseases, and aging.
Mitochondrial stem cell therapy can help restore impaired mitochondrial function, improve disease symptoms, and enhance patients' quality of life.
Results and Applicability:
GPIA has successfully developed pluripotent mitochondrial stem cells, capable of differentiating into various cell types in the body.
Preclinical studies show that GPIA's mitochondrial stem cell therapy is effective and safe in animal models of Parkinson's and Alzheimer's.
GPIA is conducting human clinical trials for mitochondrial stem cell therapies in treating Parkinson's and Alzheimer's.
Immune Cell Platform:
Research Technology:
CAR-T Technology: Develop T cells with chimeric antigen receptors (CAR), enabling them to specifically recognize and eliminate cancer cells.
CAR-NK Technology: Create NK cells with CAR receptors, enhancing their effectiveness in destroying cancer cells and minimizing side effects.
Dual-Receptor T Cell Technology: Develop T cells with dual CAR receptors, targeting two different cancer antigens, thereby increasing treatment efficacy.
Applied Technology:
Develop T cell and NK cell immunotherapies targeting cancer cells, offering higher treatment efficacy compared to traditional cancer therapies.
Cell-based immunotherapy can help the body's immune system effectively recognize and destroy cancer cells while minimizing side effects on healthy cells.
Results and Applicability:
GPIA has developed potential CAR-T therapies for blood cancers such as acute lymphoblastic leukemia and solid tumors like lung cancer.
Preclinical studies show that GPIA's CAR-T therapy is highly effective and safe in animal models of blood cancer and solid tumors.
GPIA is conducting human clinical trials for CAR-T therapies in treating acute lymphoblastic leukemia and lung cancer.
Stem Cell Platform:
Research Technology:
Embryonic Stem Cell Culturing: Culture embryonic stem cells from surplus embryos in the in vitro fertilization process.
Adult Stem Cell Culturing: Culture stem cells from mature tissues and organs in the body.
Stem Cell Differentiation: Stimulate stem cells to differentiate into specialized cells with specific functions in the body.
Applied Technology:
Develop stem cell therapies to regenerate tissues and organs damaged by disease, injury, or aging.
Stem cell therapy has the potential to cure rare and chronic diseases while restoring function to damaged tissues and organs.
Results and Applicability:
GPIA has successfully developed potential stem cells for treating cardiovascular diseases such as heart failure.
Stem Cell Storage Bank:
Application:
Safely collect and store immune cells and stem cells from clients, leveraging advanced Blockchain technology to elevate this service to new heights, providing significant advantages over traditional storage methods.
Preserve cells in optimal conditions for future use in treating incurable diseases, transparently recording all information about the collection, storage, and use of cells in a tamper-proof manner.
Blockchain-Based Cell Storage Process:
Cell Collection: Immune cells and stem cells are extracted from clients using safe medical methods.
Cell Processing: Cells are processed and prepared for storage according to strict medical standards.
Cell Storage: Cells are stored in optimal conditions using advanced technologies like liquid nitrogen.
Blockchain Information Recording: All information about the cells, from collection to storage, is recorded on the Blockchain ledger in a transparent and immutable manner.
Preservation and Management: Cells are safely preserved in the stem cell storage bank and managed by a team of experienced experts.
Development of Advanced Biopharmaceuticals:
Research Technology and Applicability:
Mitochondrial Therapy (MITO ADDâ„¢): Restore mitochondrial function, improve mitochondrial health, and treat diseases caused by mitochondrial dysfunction.
NK Cell Therapy (MYTO NKMâ„¢): Enhance the immune system, effectively destroy cancer cells with minimal side effects.
Stem Cell Therapy (C-STEMâ„¢): Regenerate damaged tissues and organs, treat rare and chronic diseases.
Immune Enhancement Therapy (S-PM CUREâ„¢): Stimulate the natural immune system to fight cancer, improving treatment efficacy.
Key Product Lines:
NK Cell Therapy (MYTO NKMâ„¢): Currently in preclinical stage, expected to file IND application in early 2025.
Mitochondrial Therapy (MITO ADDâ„¢): Currently in preclinical stage, expected to file IND application in early 2025.
Stem Cell Therapy (C-STEMâ„¢): Currently in preclinical stage, expected to file IND application in late 2025.
Immune Enhancement Therapy (S-PM CUREâ„¢): Fully developed and currently available at local clinics in South Korea.
With world-leading core research technologies, GPIA is at the forefront of developing advanced biopharmaceuticals. The therapies developed by GPIA hold great potential in regenerative medicine and immunology, contributing to improved health and quality of life for people, opening the door to a promising future in medicine.
Last updated